Dimensional Fund Advisors LP Sells 592,968 Shares of bluebird bio, Inc. (NASDAQ:BLUE)

Dimensional Fund Advisors LP cut its stake in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 98.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,906 shares of the biotechnology company’s stock after selling 592,968 shares during the period. Dimensional Fund Advisors LP owned 0.11% of bluebird bio worth $91,000 at the end of the most recent quarter.

Separately, Regeneron Pharmaceuticals Inc. acquired a new position in bluebird bio in the 4th quarter valued at $175,000. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

bluebird bio Price Performance

BLUE opened at $4.97 on Friday. The company has a market cap of $48.66 million, a P/E ratio of -0.13 and a beta of 0.27. The business’s 50-day moving average price is $4.25 and its 200-day moving average price is $6.29. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. bluebird bio, Inc. has a 12 month low of $3.20 and a 12 month high of $28.60.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BLUE. Baird R W lowered bluebird bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 21st. Wells Fargo & Company cut their target price on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a report on Monday, February 24th. Barclays cut their target price on bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a report on Monday, March 31st. JPMorgan Chase & Co. raised bluebird bio from an “underweight” rating to a “neutral” rating in a research note on Monday, February 24th. Finally, StockNews.com began coverage on bluebird bio in a research note on Thursday. They issued a “sell” rating on the stock. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $44.60.

bluebird bio Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.